An experimental cancer drug has had an impressive success rate and seems to treat almost every patient in a clinical trial.
Dustarlimab was used in a trial at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, where all 18 participants were treated for some form of rectal cancer.
Dustarlimab was given every three weeks for six months to 18 people with a type of rectal cancer in a study conducted at the center.
The drug appeared to clear up rectal cancer with minimal side effects, although scientists say it’s too early to tell if patients have been completely cured.
The participants were studied over a year of treatment, with the overall result being that the cancer had disappeared.
After the new treatment, all patients found that their cancer had cleared up on a physical exam, endoscopy, PET scan and MRI, the MSKCC researchers said.
“I think this is the first time this has happened in the history of cancer,” Dr. Luis Diaz, one of the paper’s lead authors and an oncologist at MSKCC, told the New York Times. This is a huge step forward for patients.” He added that he believed this was just the “tip of the iceberg”, according to “Mirror”.
dr. Hana Sanoff, of the University of North Carolina’s Leinberger Comprehensive Cancer Center, commented on the results of the study saying she’s very optimistic about the new treatment, noting that “we’ve never seen anything that’s 100% of the people in cancer medicine.” of drugs called immune checkpoint inhibitors. These are immunotherapy drugs that don’t work by directly attacking the cancer itself, but rather let a person’s immune system do the work in the first place.”
Follow our latest local and sports news and the latest political and economic developments via Google news